Back to
PRICE T ROWE ASSOCIATES INC /MD/
PTGX26 quarters
Position history for
PRICE T ROWE ASSOCIATES INC /MD/'s holdings in PROTAGONIST THERAPEUTICS INC
Yes. Price T Rowe Associates holds 2,149,662 shares of PTGX (Protagonist Therapeutics), worth $263.5M, as of its Q2 2026 13F filing. It increased the position by 484,165 shares (+29.1%) from Q1 2026. Price T Rowe Associates has held PTGX since Q1 2023, across 14 quarterly 13F filings.
Current Value
$263.5M
Current Shares
2.1M
Total Value Change
+$263.2M
Total Shares Change
+2.1M
Quarter-by-Quarter History
Other major holders of PTGX: BlackRock, Inc., FARALLON CAPITAL MANAGEMENT, L.L.C.